Evidence map›Paper›PMID 35439358›Full record

ArticlePhysiological reports2022

Characterization of the mechanism by which a nonsense variant in RYR2 leads to disordered calcium handling.

Claire Hopton, Anke J Tijsen, Leonid Maizels, Gil Arbel, Amira Gepstein, Nicola Bates, Benjamin Brown, Irit Huber, Susan J Kimber, William G Newman and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Physiological reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Claire HoptonDivision of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.ORCID 0000-0002-2889-4638
Anke J TijsenThe Rappaport Faculty of Medicine and Research Institute, Technion-Institute of Technology, Haifa, Israel.
Leonid MaizelsThe Rappaport Faculty of Medicine and Research Institute, Technion-Institute of Technology, Haifa, Israel.
Gil ArbelThe Rappaport Faculty of Medicine and Research Institute, Technion-Institute of Technology, Haifa, Israel.
Amira GepsteinThe Rappaport Faculty of Medicine and Research Institute, Technion-Institute of Technology, Haifa, Israel.
Nicola BatesDivision of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Benjamin BrownDepartment of Cardiology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Irit HuberThe Rappaport Faculty of Medicine and Research Institute, Technion-Institute of Technology, Haifa, Israel.
Susan J KimberDivision of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
William G NewmanDivision of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Luigi VenetucciDivision of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Lior GepsteinThe Rappaport Faculty of Medicine and Research Institute, Technion-Institute of Technology, Haifa, Israel.
Manchester Academic Health Science Centre · GBUniversity of Manchester · GBAmsterdam University Medical Centers · NLManchester University NHS Foundation Trust · GBRambam Health Care Campus · ILTel Aviv University · IL

Funding

British Heart Foundation FS/16/33/32196Department of HealthManchester NIHR BRC IS-BRC-1215-20007Medical Research Council MR/S002553/1
6 · The paper itself

Abstract

Heterozygous missense variants of the cardiac ryanodine receptor gene (RYR2) cause catecholaminergic polymorphic ventricular tachycardia (CPVT). These missense variants of RYR2 result in a gain of function of the ryanodine receptors, characterized by increased sensitivity to activation by calcium that results in an increased propensity to develop calcium waves and delayed afterdepolarizations. We have recently detected a nonsense variant in RYR2 in a young patient who suffered an unexplained cardiac arrest. To understand the mechanism by which this variant in RYR2, p.(Arg4790Ter), leads to ventricular arrhythmias, human induced pluripotent stem cells (hiPSCs) harboring the novel nonsense variant in RYR2 were generated and differentiated into cardiomyocytes (RYR2-hiPSC-CMs) and molecular and calcium handling properties were studied. RYR2-hiPSC-CMs displayed significant calcium handling abnormalities at baseline and following treatment with isoproterenol. Treatment with carvedilol and nebivolol resulted in a significant reduction in calcium handling abnormalities in the RYR2-hiPSC-CMs. Expression of the mutant RYR2 allele was confirmed at the mRNA level and partial silencing of the mutant allele resulted in a reduction in calcium handling abnormalities at baseline. The nonsense variant behaves similarly to other gain of function variants in RYR2. Carvedilol and nebivolol may be suitable treatments for patients with gain of function RYR2 variants.

Indexed as

Induced Pluripotent Stem CellsRyanodine Receptor Calcium Release ChannelCalciumCalcium SignalingCarvedilolHumansMutationMyocytes, CardiacNebivololCalciumCarvedilolNebivololRyanodine Receptor Calcium Release ChannelRyR2 protein, humanCPVThuman induced pluripotent stem cellsRYR2ventricular arrhythmia

Identifiers

PMID35439358
PMCPMC9017975
OpenAlexW4224278870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.